|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1990-11-14
|
|
pubmed:abstractText |
A phase II study of cisplatin and tegafur in recurrent epidermoid head and neck cancer is presented. All patients were treated with cisplatin 100 mg/m2 every 4 weeks. Twenty-nine received tegafur 750 mg/m2 days 2-28 orally and 18 patients, who were unable to take tegafur orally, were treated with tegafur 1,500 mg/m2 intravenously days 2-5. The response rate in the oral group was 28.5% and the median survival 29 weeks. The response rate in the intravenous group was 6% and the median survival was 17 weeks. We conclude that cisplatin and oral tegafur is active against head and neck cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0284-186X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
589-91
|
|
pubmed:dateRevised |
2009-5-12
|
|
pubmed:meshHeading |
pubmed-meshheading:2206571-Administration, Oral,
pubmed-meshheading:2206571-Adult,
pubmed-meshheading:2206571-Aged,
pubmed-meshheading:2206571-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2206571-Carcinoma, Squamous Cell,
pubmed-meshheading:2206571-Cisplatin,
pubmed-meshheading:2206571-Drug Evaluation,
pubmed-meshheading:2206571-Female,
pubmed-meshheading:2206571-Head and Neck Neoplasms,
pubmed-meshheading:2206571-Humans,
pubmed-meshheading:2206571-Injections, Intravenous,
pubmed-meshheading:2206571-Male,
pubmed-meshheading:2206571-Middle Aged,
pubmed-meshheading:2206571-Neoplasm Recurrence, Local,
pubmed-meshheading:2206571-Tegafur
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Cisplatin and tegafur in recurrent head and neck cancer. A phase II study.
|
|
pubmed:affiliation |
Department of Oncology ONA, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
